Adán Oliveros-Ceballos1*, Janeth Gutiérrez-Segura2, Adrian Israel Ramirez-Mendoza3 and Bryan Adan Oliveros-Galeana4
1Director of Reproduction and Gyneacology of Acapulco Institute (IREGA), Guerrero, México
2Adscrit Pneumologist to Regional Hospital No 1 Vicente Guerrero of Acapulco Covid-19 Area, México
3Adscrit to Maternal Fetal Unit, México
4Adscrit to Biology of Reproduction Unit, México
*Corresponding Author: Adán Oliveros-Ceballos, Director of Reproduction and Gyneacology of Acapulco Institute (IREGA), Guerrero, México.
Received: June 05, 2020; Published: July 30, 2020
Objective: This study aims to describe the clinical results of a miniseries of 6 patients who presented characteristic COVID-19 symptoms and PCR positive, who were administered Etanercept, to avoid Cytokine release syndrome with the purpose of decreasing admission to the critical care unit.
Design: This is a prospective, descriptive observational study.
Patients and Methods: 6 patients with (SARS-CoV-2) COVID-19 symptoms were evaluated for the administration of the immunomodulator Etanercept 50 mg. Two groups were aligned: A) Mild: with fever, cough, images compatible with pneumonia, and gastrointestinal symptoms; B) Moderate: with fever, cough, images compatible with pneumonia, gastrointestinal symptoms and respiratory distress considered as L phenotype.
Results: A total of 13 patients were identified with suspected infection of the virus (SARS-CoV-2) COVID-19, from which 6 patients accepted the administration of the immunomodulator Etanercept 50 mg (subcutaneous) in a single dose and protocol follow-up. From these 6 patients: 4 patients had fever, cough, headache and risk factors such as pregnancy and obesity; and 2 patients also presented respiratory distress considered as L phenotype. All 6 evolved to improvement.
No patient was admitted to the critical intensive care unit and did not require invasive ventilatory support.
Conclusion: In this miniseries, the administration of the Etanercept immunomodulator in patients with (SARS-CoV-2) from mild to moderate stage, improved the clinical evolution and reduced the risk of admission to the intensive care unit. However, more patients and more controlled and randomized studies are necessary to recommend immunomodulators.
Keywords: COVID-19; Acute Respiratory Distress Syndrome (ARDS); Cytokine Storm; Inflammation; Anti-Inflammatory, Self-Induced Lung Damage (DPA); Tumor Necrosis Factor (TNF)
Citation: Adán Oliveros-Ceballos., et al. “Use of Immunomodulators (Etanercept) in a Miniseries with Covid-19 Patients, to Decrease the Progress of Complications and Risks of Entry into Critical Care. Bibliography Review". Acta Scientific Women's Health 2.8 (2020): 08-18.
Copyright: © 2020 Adán Oliveros-Ceballos., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.